NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.)

NBIXのニュース

   Neurocrine Biosciences Q2 2021 Earnings Preview  2021/08/02 21:35:55 Seeking Alpha
   Immunotoxins Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences,   2021/07/25 14:19:10 Jumbo News
This report studies the Immunotoxins Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Immunotoxins market segmented by company, region, type and applications []
   United States Parkinson''s Disease Market Insights, Epidemiology and Outlook to 2030 | Addex Pharma, AbbVie, Prevail Therapeutics, Denali Therapeutics, Neurocrine Biosciences, and More  2021/07/23 20:45:00 Business Insider Markets
DUBLIN, July 23, 2021 /PRNewswire/ -- The
   Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results  2021/07/19 20:01:00 PR Newswire
SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its
   Essential Tremor Treatment Market Growth 2021-2026: Merz Pharma GmbH & Co KgaA , Neurocrine Biosciences Inc , Sage Therapeutics Inc  2021/07/09 13:45:02 Tramways Monthly
Essential Tremor Treatment Market analysis report is sure to help boost sales and improve return on investment (ROI). The research and analysis carried out in this Essential Tremor Treatment Market report assist clients to forecast investment in an emerging market, expansion of market share or success of a new product with the help of global […]
   Neurocrine Biosciences presents new muscarinic M4 receptor antagonists  2021/07/02 13:58:09 BioWorld
   Idorsia: Putting The Capstone On A Foundationally Strong Biotech  2021/06/10 17:51:23 Seeking Alpha
   Hematuria Treatment Market 2028 Analysis of Key Players Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals  2021/06/01 16:17:28 OpenPR
A new market report by The Insight Partners on the Hematuria Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of
   Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/01 00:00:00 BioSpace
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.
   Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX  2021/05/26 13:25:00 Seeking Alpha
   Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)  2021/03/02 12:30:00 PR Newswire
SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by…
   Malcolm Lloyd-Smith Sells 865 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/02/11 12:00:41 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 865 shares of the firm’s stock in a transaction on Friday, February 5th. The stock was sold at an average price of $114.15, for a total value of $98,739.75. Following the sale, the insider now owns 29,675 shares in the company, valued at approximately $3,387,401.25. The transaction […]
   Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $275,951.14 in Stock  2021/02/10 02:56:57 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,363 shares of the firm’s stock in a transaction on Monday, February 8th. The shares were sold at an average price of $116.78, for a total value of $275,951.14. Following the completion of the transaction, the insider now owns 17,231 shares of the company’s stock, valued at […]
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences

calendar